Experimental HCV Drugs
Experimental HCV Drugs
Investigational HCV Inhibitor TMC435 Demonstrates Promising Safety and Efficacy in Phase 1 Study
- Details
- Category: Experimental HCV Drugs
- Published on Friday, 02 April 2010 14:02
- Written by Liz Highleyman
Tibotec's investigational hepatitis C virus (HCV) NS3/4A protease inhibitor TMC435 demonstrated good antiviral activity and appeared to be safe and generally well-tolerated in a Phase 1 placebo-controlled clinical trial, according to a report in the March 2010 Gastroenterology.
AASLD 2009: Boosted Narlaprevir plus Pegylated Interferon and Ribavirin Leads to Rapid Viral Suppression in Genotype 1 Hepatitis C Patients
- Details
- Category: HCV Treatment
- Published on Tuesday, 10 November 2009 12:46
- Written by HIVandHepatitis.com
In the NEXT-1 study, presented at the 60th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD 2009) last week in Boston, the experimental HCV NS3 protease inhibitor narlaprevir (formerly SCH 900518), boosted with ritonavir, demonstrated potent antiviral activity in combination with pegylated interferon and ribavirin among treatment-naive patients with genotype 1 chronic hepatitis C. Across the doses tested, 53% to 87% of narlaprevir recipients achieved undetectable HCV RNA by week 4. Nalraprevir/ritonavir demonstrated no unique or treatment-limiting adverse effects.
EASL 2009: Antiviral Agents with Activity against Both HIV and Hepatitis C Virus
- Details
- Category: Experimental HCV Drugs
- Published on Tuesday, 02 June 2009 13:47
- Written by Liz Highleyman
Standard therapy for chronic hepatitis C virus (HCV) infection consists of pegylated interferon plus ribavirin, but several novel agents under study directly target various steps of the HCV lifecycle, an approach known as "STAT-C." Some of these investigational agents work similarly to certain antiretroviral drugs for HIV, suggesting it may be possible to develop drugs that have activity against both HIV-HCV, a potential benefit for HIV-HCV coinfected patients.
Pharmasset Selects Investigational HCV Polymerase Inhibitor PSI-879 for Preclinical Development
- Details
- Category: HCV Treatment
- Published on Friday, 09 October 2009 14:01
- Written by Pharmasset
Pharmasset, Inc. recently announced that it has chosen its experimental hepatitis C virus (HCV) polymerase inhibitor PSI-352879 (or PSI-879 for short) -- a purine nucleotide analog -- as a candidate for further preclinical development. PSI-879, as well as the company's other investigational nucleoside/nucleotide analogs, may potentially be suitable for use in combination regimens with other directly-targeted oral anti-HCV drugs now in the pipeline.
Researchers Present Data on Investigational Cyclophilin Inhibitors Debio 025 and SCY-635
- Details
- Category: HCV Treatment
- Published on Friday, 15 May 2009 13:47
- Written by Liz Highleyman
At the 44th Annual Meeting of the European Association for the Study of the Liver (EASL 2009) last month in Copenhagen, researchers presented promising data from studies of a new class of agents for HCV therapy, cyclophilin inhibitors.
More Articles...
- Adding Telaprevir Improves Sustained Response to Pegylated Interferon plus Ribavirin in Genotype 1 Chronic Hepatitis C Patients (PROVE3)
- Abbott and Enanta Announce First Clinical Trial of Oral HCV Protease Inhibitor ABT-450
- Nitazoxanide Enhances Anti-HCV Activity of Pegylated interferon/ribavirin and STAT-C Agents
- AASLD 2008: Investigational HCV Protease Inhibitor BI 201335 Exhibits Promising Antiviral Activity
Web Design and Development by